Zhang Luhan, Li Wenjing, Chi Xiaolan, Sun Qi, Li Yuanyuan, Xing Weiwei, Ding Guifeng
Xinjiang Clinical Research Center for Perinatal Diseases, Urumqi Maternal and Child Health Hospital, Urumqi, Xinjiang Uygur Autonomous Region, China.
Medical Research Design and Data Analysis Center, Traditional Chinese Medicine Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, China.
J Gynecol Obstet Hum Reprod. 2025 Apr;54(4):102925. doi: 10.1016/j.jogoh.2025.102925. Epub 2025 Feb 11.
It is difficult to evaluate whether monitoring serum sFlt-1, PlGF, or sFlt-1/PlGF in pregnant women who are suspected of having PE can significantly shorten the PE diagnosis time.
To estimate the accuracy of sFlt-1, PlGF and sFlt-1/PlGF in preeclampsia prediction.
Databases including PubMed, Web of Science, Medline, CNKI, SinoMed, VIP Journal, and Wanfang Data were searched for eligible studies published until October 7, 2022.
The research subjects were pregnant women with or without PE. The research types were case-control studies and cohort studies. This was an original study involving the detection of at least one of the following in the blood, serum or plasma: sFlt-1, PlGF, and sFlt-1/PlGF.
StataSE 16.0 was employed, using the Sen, Spe, PLR, and NLR to plot SROC, and subgroup analysis and meta-regression were conducted.
Meta-analysis showed that the combined Sen of sFlt, PlGF and sFlt-1/PlGF was 0.79 (95 % CI: 0.68-0.87), 0.76 (95 % CI: 0.69-0.82), and 0.83 (95 % CI: 0.77-0.88), respectively; the Spe was 0.86 (95 % CI: 0.77-0.92), 0.83 (95 % CI: 0.78-0.88), and 0.88 (95 % CI: 0.82-0.92), respectively; and the AUC was 0.89, 0.87, and 0.92, respectively. It was found to be attributable to study design, literature quality, sample size, disease subtypes, and cut-off values by using subgroup analysis and meta-regression.
The sFlt-1/PlGF ratio showed better predictive performance for preeclampsia than sFlt-1 or PlGF alone. However, the predictive value of the latter two cannot be ignored.This study highlights the performance of biomarkers in the diagnosis and prediction of PE, but that there is currently a lack of data to assess the value of using these biomarkers in clinical practice, and that the use of these biomarkers has not yet been shown to improve pregnancy outcomes.
对于疑似患有肺栓塞(PE)的孕妇,很难评估监测血清可溶性血管内皮生长因子受体-1(sFlt-1)、胎盘生长因子(PlGF)或sFlt-1/PlGF是否能显著缩短PE诊断时间。
评估sFlt-1、PlGF及sFlt-1/PlGF预测子痫前期的准确性。
检索了包括PubMed、科学网、Medline、中国知网、中国生物医学文献数据库、维普资讯和万方数据在内的数据库,以查找截至2022年10月7日发表的符合条件的研究。
研究对象为患有或未患PE的孕妇。研究类型为病例对照研究和队列研究。这是一项原创性研究,涉及在血液、血清或血浆中检测以下至少一种物质:sFlt-1、PlGF和sFlt-1/PlGF。
采用StataSE 16.0,使用敏感度(Sen)、特异度(Spe)、阳性似然比(PLR)和阴性似然比(NLR)绘制综合受试者工作特征曲线(SROC),并进行亚组分析和Meta回归。
Meta分析显示,sFlt-1、PlGF和sFlt-1/PlGF的合并敏感度分别为0.79(95%可信区间:0.68-0.87)、0.76(95%可信区间:0.69-0.82)和0.83(95%可信区间:0.77-0.88);特异度分别为0.86(95%可信区间:0.77-0.92)、0.83(95%可信区间:0.78-0.88)和0.88(95%可信区间:0.82-0.92);曲线下面积(AUC)分别为0.89、0.87和0.92。通过亚组分析和Meta回归发现,这可归因于研究设计、文献质量、样本量、疾病亚型和截断值。
sFlt-1/PlGF比值对子痫前期的预测性能优于单独的sFlt-1或PlGF。然而,后两者的预测价值也不容忽视。本研究突出了生物标志物在PE诊断和预测中的性能,但目前缺乏数据来评估在临床实践中使用这些生物标志物的价值,且尚未证明使用这些生物标志物能改善妊娠结局。